Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Pfizer
Eli Lilly and Company
Astellas Pharma Inc
AstraZeneca
Johnson & Johnson Enterprise Innovation Inc.
Kortuc, Inc.
Genmab
Coherus Oncology, Inc.
Eli Lilly and Company
iOnctura
Merck Sharp & Dohme LLC
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Pfizer
R-Pharm
AstraZeneca
HC Biopharma Inc.
GlaxoSmithKline
Boehringer Ingelheim
InSilico Medicine Hong Kong Limited
Fate Therapeutics
Tesaro, Inc.
AbbVie
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
EMD Serono
BeiGene
Eli Lilly and Company
Leap Therapeutics, Inc.
Toray Industries, Inc
ALX Oncology Inc.
HRYZ Biotech Co.
Merck Sharp & Dohme LLC
Daiichi Sankyo
Jiangsu Hansoh Pharmaceutical Co., Ltd.
AstraZeneca
Innovent Biologics (Suzhou) Co. Ltd.
AstraZeneca
GlaxoSmithKline
Genentech, Inc.
Eli Lilly and Company
EMD Serono
Taiho Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Bristol-Myers Squibb
Gilead Sciences
Celgene
AstraZeneca